These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37539782)

  • 21. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remdesivir for severe covid-19: a clinical practice guideline.
    Rochwerg B; Agarwal A; Zeng L; Leo YS; Appiah JA; Agoritsas T; Bartoszko J; Brignardello-Petersen R; Ergan B; Ge L; Geduld H; Gershengorn HB; Manai H; Huang M; Lamontagne F; Kanda S; Kawano-Dourado L; Kurian L; Kwizera A; Murthy S; Qadir N; Siemieniuk R; Silvestre MA; Vandvik PO; Ye Z; Zeraatkar D; Guyatt G
    BMJ; 2020 Jul; 370():m2924. PubMed ID: 32732352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.
    Elsawah HK; Elsokary MA; Abdallah MS; ElShafie AH
    Rev Med Virol; 2021 Jul; 31(4):e2187. PubMed ID: 33128490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis.
    Lee TC; Murthy S; Del Corpo O; Senécal J; Butler-Laporte G; Sohani ZN; Brophy JM; McDonald EG
    Clin Microbiol Infect; 2022 Sep; 28(9):1203-1210. PubMed ID: 35598856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remdesivir-associated bradycardia.
    Ching PR; Lee C
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of remdesivir in patients with COVID-19: a systematic review and meta-analysis.
    Tanni SE; Silvinato A; Floriano I; Bacha HA; Barbosa AN; Bernardo WM
    J Bras Pneumol; 2022; 48(1):e20210393. PubMed ID: 35137874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Wang CY; Chen KH; Wang YH; Hsueh PR
    J Antimicrob Chemother; 2021 Jul; 76(8):1962-1968. PubMed ID: 33758946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study.
    Abedipour F; Mirzaei HH; Ansari H; Ehsanzadeh N; Rashki A; Vahedi MM; Rashki A
    Drug Res (Stuttg); 2024 Jul; 74(6):290-295. PubMed ID: 38968952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.
    Pantazopoulos I; Mavrovounis G; Dimeas G; Zikos N; Pitsikou M; Rousogianni E; Mermiri M; Michou A; Spanos M; Maniotis C; Chalkias A; Laou E; Zakynthinos G; Chatzis D; Gourgoulianis K
    Am J Cardiovasc Drugs; 2022 Nov; 22(6):705-710. PubMed ID: 36002783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remdesivir-associated bradycardia in COVID-19: a rapid review protocol.
    Tian E; Cosme C; Bauzon J; Batra K; Azar F; Schreiber A
    BMJ Open; 2023 May; 13(5):e068564. PubMed ID: 37258075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
    Jung SY; Kim MS; Li H; Lee KH; Koyanagi A; Solmi M; Kronbichler A; Dragioti E; Tizaoui K; Cargnin S; Terrazzino S; Hong SH; Abou Ghayda R; Kim NK; Chung SK; Jacob L; Salem JE; Yon DK; Lee SW; Kostev K; Kim AY; Jung JW; Choi JY; Shin JS; Park SJ; Choi SW; Ban K; Moon SH; Go YY; Shin JI; Smith L
    Clin Transl Sci; 2022 Feb; 15(2):501-513. PubMed ID: 34719115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.
    Day LB; Abdel-Qadir H; Fralick M
    CMAJ; 2021 Apr; 193(17):E612-E615. PubMed ID: 33903133
    [No Abstract]   [Full Text] [Related]  

  • 34. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
    Nasir M; Talha KA; Islam T; Saha SK; Selina F; Parveen RA
    Mymensingh Med J; 2020 Apr; 29(2):481-487. PubMed ID: 32506110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).
    Pallotto C; Suardi LR; Gabbuti A; Esperti S; Mecocci L; Blanc P
    J Med Virol; 2021 May; 93(5):2631-2634. PubMed ID: 33620107
    [No Abstract]   [Full Text] [Related]  

  • 37. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial.
    Tam AR; Zhang RR; Lung KC; Liu R; Leung KY; Liu D; Fan Y; Lu L; Lam AH; Chung TW; Yip CC; Lo J; Wu AK; Lee R; Sin S; Ng PY; Chan WM; Shum HP; Yan WW; Chan JF; Cheng VC; Lau CS; To KK; Chan KH; Yuen KY; Hung IF
    Clin Infect Dis; 2023 Feb; 76(3):e216-e226. PubMed ID: 35762834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
    Sellers J; Chang J; Jones J; Hintze TD
    Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.